Lexeo Therapeutics (LXEO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with board members, management, and external advisors present.
Agenda and rules of conduct posted on the virtual meeting website; stockholders instructed to follow them.
The meeting would address and vote on two proposals, with a Q&A session to follow after adjournment.
Shareholder proposals
Proposal 1: Election of three Class III directors for a three-year term expiring in 2029.
Proposal 2: Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Overview of voting outcomes
Quorum confirmed with sufficient shares present in person or by proxy.
Both proposals passed: directors elected and KPMG LLP ratified as auditor.
Final voting results to be filed on Form 8-K within four business days.
Latest events from Lexeo Therapeutics
- Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway.LXEO
Corporate presentation - LX2006 pivotal trial and LX2020 RMAT status drive progress; cash runway extends into 2028.LXEO
Q2 2026 - Gene therapies for cardiac diseases show strong safety, efficacy, and regulatory progress.LXEO
J.P. Morgan Biotech: CEO Fireside Series – Lexeo Therapeutics (LXEO) - Phase III FACM study is well-powered, showing strong efficacy and regulatory momentum.LXEO
Fireside chat - Gene therapies for rare cardiac diseases advance with strong clinical data and key milestones ahead.LXEO
Corporate presentation - Gene therapy pipeline shows strong interim efficacy and safety, with major data readouts due in 2025.LXEO
Piper Sandler 36th Annual Healthcare Conference - Multiple gene therapy programs near key data readouts, targeting major cardiac and CNS diseases.LXEO
Chardan's 8th Annual Genetic Medicines Conference - LX1001 showed dose-dependent APOE2 expression, reduced tau, and no ARIA in APOE4 Alzheimer's.LXEO
Study Update - LX2006 shows robust safety and sustained cardiac biomarker improvements in FA cardiomyopathy.LXEO
Study Update